Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 9/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 8/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | KIT | P10721 | 6/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.44 |
| ▸ | FLT3 | P36888 | 6/20 | 0.44 |
| ▸ | HSPH1 | Q92598 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499144 | 1.00 | PLK1 (0.48) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL4488258 | 0.95 | PLK1 (0.42) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL4488257 | 0.95 | PLK1 (0.42) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL4496876 | 0.94 | PLK1 (0.48) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL4496879 | 0.94 | PLK1 (0.48) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL226576 | 0.93 | PLK1 (0.49) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL226575 | 0.93 | PLK1 (0.49) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL4493366 | 0.92 | PLK1 (0.40) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL4493362 | 0.92 | PLK1 (0.40) | PLK1PLK3PDGFRBKDRKIT | |
| SCHEMBL4500854 | 0.90 | LPAR1 (0.39) | PLK1PLK3PDGFRBKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | PLK1 86/4885PLK3 133/4885PDGFRB 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.